The World Health Organization now describes the Bundibugyo virus outbreak in the Democratic Republic of the Congo as the largest Ebola outbreak ever reported in that country, surpassing the 2018 to 2020 epidemic that had held the record.
As of July 30, WHO reported 3,605 confirmed cases and 1,587 deaths in the DRC, a crude case fatality ratio of 44 percent. The agency also reported the outbreak's worst week to date. During epidemiological week 30, health authorities recorded 567 cases and 296 deaths, the highest weekly figures since transmission began.
For American households, the practical stake is not infection risk inside the United States, which federal health officials continue to describe as low. It is the countermeasure gap. This is a strain of Ebola for which no licensed vaccine and no approved treatment exist, and the U.S. response has therefore leaned almost entirely on border screening and entry restrictions that must be renewed roughly every 30 days.
Scale That Has Overtaken Every Previous Congolese Outbreak
The outbreak began in a single health zone. According to WHO's latest Disease Outbreak News, it has since expanded to five provinces, Ituri, North Kivu, South Kivu, Haut-Uele and Tshopo, and now affects 49 health zones.
WHO stated plainly in its summary that "this is now the largest Ebola outbreak ever reported in the country." Since the previous outbreak news published in mid-July, an additional 1,481 confirmed cases and 759 confirmed deaths were reported. WHO attributes part of that jump to expanded surveillance and laboratory capacity, but says most of it reflects real expansion of the outbreak.
At least 651 people in the DRC have recovered. Insecurity, population displacement and cross-border movement continue to complicate the response, according to the agency.
There is one piece of positive news in the same reporting period. Uganda's Ministry of Health declared its outbreak over on July 28, saying "today, Uganda is Ebola free." Uganda recorded 20 confirmed cases and two deaths, with 18 recoveries, and its last confirmed case was reported in late June.
A Strain Left Behind by the Tools Built for Zaire Ebola
Bundibugyo virus is a distinct species within the same family as the Zaire strain that caused the 2014 to 2016 West Africa epidemic. That distinction is the central medical problem here.
The two licensed Ebola vaccines, Ervebo and the Mvabea and Zabdeno regimen, target Zaire ebolavirus. WHO has judged the evidence for cross-protection against Bundibugyo insufficient and has advised against deploying them in this outbreak. Approved monoclonal antibody treatments for Zaire Ebola are likewise not authorized for this species. Care is supportive, and early supportive care is what saves lives.
That gap is now the focus of active research. Trials of the antiviral remdesivir and the monoclonal antibody MBP134 began in the DRC in early July. Later that month, enrollment opened in EBO-PEP, a trial of Gilead's experimental antiviral obeldesivir as post-exposure prophylaxis, run in Ituri province by the National Institute for Biomedical Research in Kinshasa. Researchers aim to enroll close to 1,000 people who had direct contact with a confirmed case within the previous five days. WHO Director-General Dr. Tedros Adhanom Ghebreyesus said a successful result could establish prophylaxis as "a game-changing approach for preventing Ebola disease."
None of these products has regulatory approval for Bundibugyo virus, and no trial results have been published. Readers should treat all of them as investigational.
Border Screening Still Standing Between the Outbreak and U.S. Households
No case of Bundibugyo virus disease has been confirmed inside the United States from this outbreak. Two American aid workers infected in the DRC were medically evacuated to Germany in May and July.
U.S. air passengers arriving from the DRC, Uganda or South Sudan are still routed to four designated airports for enhanced public health entry screening, according to the CDC's Ebola question and answer page: Washington Dulles, Atlanta Hartsfield-Jackson, Houston's George Bush Intercontinental and New York's John F. Kennedy. MedicalDaily previously reported on the third consecutive 30-day renewal of those entry restrictions, issued in mid-July and running through roughly August 12.
The households most directly affected are a specific and identifiable group: aid workers, missionaries, health care volunteers, researchers and people with family in eastern DRC, along with travelers connecting through the affected region. The State Department maintains a do-not-travel advisory for the DRC tied to the outbreak.
Uganda's declaration does not by itself change the U.S. screening list, since that order also covers the DRC and South Sudan. Whether federal officials narrow the country list at the next renewal is one of the practical questions this development raises.
Signals to Track Over the Coming Weeks
The most important number to watch is not the cumulative death toll. It is the weekly case count. A cumulative figure only rises. A declining weekly count would be the first credible sign that the response has caught up with transmission, and week 30 moved in the wrong direction.
WHO has repeatedly cautioned that reported figures understate the true scale, citing surveillance gaps in a conflict-affected region. The European Center for Disease Prevention and Control publishes its own running tally drawn from Congolese ministry situation reports, and its numbers frequently differ from WHO's because the two use different data cutoffs. That is a reporting-period difference, not a contradiction.
Three things remain unconfirmed: the true infection total, whether any experimental countermeasure works against this species, and whether the current U.S. entry order will be renewed around mid August. Travelers returning from affected areas should monitor for symptoms for 21 days and contact their local health department or clinician before seeking in-person care, so that facilities can prepare. MedicalDaily will report on the next WHO situation report and on any change to the U.S. entry order.
Frequently Asked Questions
What changed in this update? WHO stated that this is now the largest Ebola outbreak ever recorded in the DRC, surpassing the 2018 to 2020 epidemic, and reported the highest weekly case and death totals of the outbreak so far.
How many cases and deaths are confirmed? As of July 30, WHO reported 3,605 confirmed cases and 1,587 deaths in the DRC. Uganda reported 20 cases and two deaths before declaring its outbreak over.
Is there a vaccine for this strain? No. The licensed Ebola vaccines target the Zaire strain, and WHO has advised against using them here because cross-protection against Bundibugyo has not been established.
Is anyone in the United States at risk? No U.S. cases have been confirmed from this outbreak, and CDC assesses domestic risk as low. The people facing real exposure risk are those traveling to or working in affected areas of eastern DRC.
What screening is in place at U.S. airports? Travelers arriving from the DRC, Uganda or South Sudan are routed to Dulles, Atlanta, Houston Intercontinental or JFK for enhanced public health entry screening under an order that requires periodic renewal.
What should someone returning from the region do? Monitor for symptoms such as fever, severe weakness, vomiting or diarrhea for 21 days after leaving, and call a clinician or local health department before going in person so the facility can prepare.
Why does Uganda's declaration not end the emergency? Uganda's outbreak arose from imported cases and its transmission chains were fully traced. Sustained transmission continues in the DRC, where the vast majority of cases are occurring.
